Vipidia
·
- Prescription status not stated
- Digestion, stomach, diabetes and nutrition
- Active substance
- Alogliptin benzoate
- Made by
- Takeda Pharma A/S
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Takeda Pharma A/S |
|---|---|
| Active substance | Alogliptin benzoate |
| Used in | Digestion, stomach, diabetes and nutrition |
| Classification | A10BH04 · Digestion, stomach, diabetes and nutrition |
| Authorised on | 2013-09-18 |
| Last updated by the regulator | 2023-07-21 |
| EMA product number | EMEA/H/C/002182 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).